<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HAEMOPHILUS b CONJUGATE VACCINE (HIB)</span><br/>(hee-mof'il-us)<br/><span class="topboxtradename">HibTITER, </span><span class="topboxtradename">PedvaxHIB, </span><span class="topboxtradename">ProHIBiT<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">vaccine</span><br/><b>Prototype: </b>Hepatitis B vaccine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>7.5 mcg, 10 mcg, 15 mcg, 25 mcg injection</p>
<h1><a name="action">Actions</a></h1>
<p>A highly purified capsular polysaccharide extracted from <i>Haemophilus influenzae</i> type b (Hib). Hib capsular polysaccharide, principal antigen in the vaccine, promotes production of Hib anticapsular antibodies.
         It mediates complement-dependent bacteriolyses of <i>H. influenzae</i> type b organism. Serum antibody response is age dependent; i.e., response is poor in infants, increasing significantly between
         1224 mo.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The vaccine produces antibodies effective against <i>H. influenza</i> type b.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To provide active immunity to <i>H. influenzae</i> type b (Hib) infection in children 2 mo5 y.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Adults at risk of Hib infection who have Hodgkin's disease, before immunosuppressive chemotherapy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component of vaccine (e.g., thiomersal); febrile illness (other than upper respiratory tract infection);
         active infection. Safe use during pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Immunoprophylaxis for <i>H. influenzae</i> type b Infection</span><br/><span class="rdage">Child:</span> <span class="rdroute">IM</span>
<i>26 mo</i>, HibTITER 0.5 mL, 3 doses 2 mo apart with booster at 15 mo; PedvaxHIB 0.5 mL, 2 doses 2 mo apart with booster at 12 mo <i>711 mo</i>, HibTITER 0.5 mL, 2 doses 2 mo apart with booster at 15 mo; PedvaxHIB 0.5 mL, 2 doses 2 mo apart with booster at 15 mo <i>1214 mo</i>, HibTITER 0.5 mL, 1 dose with booster at 15 mo; PedvaxHIB 0.5 mL, 1 dose with booster at 15 mo <i>15 mo5 y</i>, all vaccines 0.5 mL as 1 dose<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute lyophilized powder with supplied diluent.</li>
<li>
            				Note: Use different sites when giving Hib polysaccharide vaccine and DPT (diphtheria, pertussis, tetanus) at the same time.
            			
         </li>
<li>Store at 2°8° C (36°46° F); may be frozen without loss of potency. Do not freeze the diluent.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Irritation at injection site (49%). <span class="typehead">Other:</span> Acute febrile reactions (13%), irritability, anorexia, <span class="speceff-life">anaphylactoid reaction</span> (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Hib polysaccharide vaccine may interfere with interpretation of <span class="alt">antigen detection tests</span> (e.g., latex agglutination) used in diagnosis of systemic Hib disease.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">immunosuppressant drugs</span>, <span class="classification">steroids</span> may decrease antibody response. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Antibody levels detected within 2 wk. <span class="typehead">Peak:</span> 3 wk. <span class="typehead">Duration:</span> 1.53.5 y. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be prepared for anaphylactoid reaction (see Appendix F) by having epinephrine 1:1000 available.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Local reactions to the vaccine at the injection site (erythema, tenderness, induration, swelling, pain) may appear within
            6 h after administration; usually symptoms are mild and disappear in 24 h.
            						
         </li>
<li>Monitor temperature after injection. An acute febrile reaction with temperature above 38.3° C (101° F) may follow
            vaccination (less than 1% of recipients). Notify physician.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>